Latest PDX Stories
FORT WORTH, Texas, June 25 /PRNewswire/ -- PDX, a leading pharmacy technology provider, and mscripts, a leader in mobile pharmacy technology, today announced an integrated offering that allows PDX Pharmacy System users to communicate with their patients through a variety of mobile communication pathways using the mscripts platform.
PORTLAND, Ore., Feb. 25 /PRNewswire/ -- On Sunday, March 21, Portland Global Initiatives, the nonprofit arm of Portland Roasting Coffee Company, will host the second annual World Water Day PDX Walk for Water at the World Trade Center, located at SW First and Salmon Streets in downtown Portland.
The Rx.com Electronic Pharmacy Record (EPR) to Integrate with Microsoft(R) HealthVault(TM) FORT WORTH, Texas, June 9 /PRNewswire/ -- PDX and Rx.com have entered into a strategic agreement with Microsoft to make prescription data, which Rx.com manages for multiple chain and independent pharmacy clients, available to Microsoft HealthVault users by accessing a single site with aggregated prescription data.
Supermarket Gains Latest Pharmacy Management Technology, Will Offer Patients Any-Store Refills FORT WORTH, Texas, June 4 /PRNewswire/ -- Boise, Idaho-based Albertson's, LLC has selected PDX and affiliates Rx.com and NHIN as its turnkey partners of choice for its pharmacy technology solution.
Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported results for the third quarter of 2008. For the three months ended September 30, 2008, the Company reported a net loss of $13.2 million, or ($0.16) per share.
Allos Therapeutics, Inc.
By ERIK ROBINSON Representatives of Portland International Airport will have an open house next week in Vancouver to air plans to expand the north runway, manage airport noise and improve water quality. The Port of Portland will host the open house from 5:30 to 7:30 p.m.
Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported results for the second quarter of 2008. For the three months ended June 30, 2008, the Company reported a net loss of $11.8 million, or ($0.16) per share.
Allos Therapeutics has started patient enrollment in a Phase II, open-label, single-arm, multi-center study of pralatrexate in patients with advanced or metastatic relapsed transitional cell carcinoma of the urinary bladder.
- A political dynamiter.